Mauritius-based Stream Value Fund has agreed to join hands with Transgene Biotek, a pharmaceutical company. It will join the company on a long-term basis to support its drug discovery activity, in return for equity participation and certain rewards on drug licensing or sale.
The Mauritius Fund, which invests in CSR and sustainable finance initiatives in Asia, Africa, etc, is a registered FII with the SEBI.
Recently, the Transgene Biotek sold undisclosed quantum of stake to a foreign institutional investor as a result of which the company's shares will be delisted from domestic stock exchanges. Further, the company is in the process of sending the postal ballot to all its shareholders seeking their approval.
Transgene Biotek, is a biotechnology company. It is involved in the development of several cutting edge technologies.
